Botanix Pharmaceuticals Limited · ASX:BOT
Botanix Pharmaceuticals — Investor Presentation (April 2017)
32 slides from Botanix Pharmaceuticals's investor presentation, Apr 5, 2017
Slide 1: ASX/Media Release: Capital Raising Presentation
ASX/Media Release 5 April 2017 For personal use only Capital Raising Presentation Philadelphia PA and Sydney Australia, 5 April 2017: Medical dermatology company Botanix Pharmaceuticals Limited (ASX: BOT, “Botanix” or the “Company”) is pleased to provide the attached investor presentation. The prese
Slide 2: Capital Raising Presentation, April 2017
For personal use only Capital Raising Presentation April 2017
Slide 3: Capital raising summary
For personal use only + Capital raising summary
Slide 4: Capital raising overview
+Capital raising overview For personal use only Received commitments to raise up to A$7.4m via an oversubscribed Placement; will introduce a number of leading institutional and sophisticated investors to the register ▪ Capital raising via a Placement to institutional and sophisticated investors to r
Slide 5: Use of funds
+Use of funds For personal use only Compelling use of funds to accelerate the clinical programs of pipeline products and PermetrexTM commercial opportunities Overview ▪ Dual development of BTX 1503 (acne) and BTX 1204 (dermatitis) improves the probability of clinical success and enhances Botanix’s v
Slide 6: Capital raising timetable
+Capital raising timetable For personal use only Botanix is working to the indicative timetable laid out below Indicative capital raising timetable1 Trading halt Friday, 31 March 2017 Closing date for receipt of firm and irrevocable bids (4pm AWST) Monday, 3 April 2017 Allocations and offer confirma
Slide 7: Overview of Botanix Pharmaceuticals
For personal use only + Overview of Botanix Pharmaceuticals
Slide 8: Investment highlights
+Investment highlights For personal use only Botanix is one of the most compelling emerging companies on the ASX ▪ Experienced US based leadership team with FDA approvals track record ▪ Growing, multi-billion dollar dermatology markets with no new products approved in last 20 years (for acne) ▪ Key
Slide 9: Corporate overview
+Corporate overview For personal use only Innovative medical dermatology company with a clear path to commercialisation, and a highly aligned Board and management team holding 39% of Botanix shares Trading information Share price performance Share price (30-Mar-17) A$0.068 Share price (A$) Volume (m
Slide 10: Recent corporate and product development
+Recent corporate and product development For personal use only Recent corporate developments have provided a strong platform for Botanix to accelerate its clinical development program Corporate milestones Mar 2016 Jul 2016 Jul 2016 to Feb 2017 Feb 2017 Apr/May 2017 Pre-RTO: Bone Completed RTO and K
Slide 11: Senior leadership: track record of success
+Senior leadership: track record of success For personal use only Proven industry professionals with a demonstrated ability to lead the development, financing, regulatory approval and commercialisation of pharmaceuticals Expertise: corporate + IP 20+ FDA approved products Mr Matthew Callahan credite
Slide 12: Strategic and commercialisation focus
+Strategic and commercialisation focus For personal use only Primary strategy is commercialising BTX 1503, with supportive pipeline of other medical dermatology products Active pharmaceutical Cannabidiol Botanix product BTX 1503 PermetrexTM BTX 1308 BTX 1204 Delivery technology Clinical application
Slide 13: Significant and growing market opportunity
+Significant and growing market opportunity For personal use only Global acne prescription products market expected to grow to >US$4.5bn by 2018, driven by the significant US market and is only a subset of the global dermatology opportunity Value of the global acne prescription market is Top branded
Slide 14: Botanix's most advanced product – BTX 1503
+Botanix’s most advanced product – BTX 1503 For personal use only BTX 1503 is topically applied for the treatment of moderate and severe acne utilising a novel skin delivery technology called PermetrexTM Overview Cannabidiol mechanism of action in acne ▪ BTX 1503 is a formulation of pure, synthetic
Slide 15: BTX 1503 market positioning
+BTX 1503 market positioning For personal use only BTX 1503 has the potential to be the market leading product for acne treatment with no undesirable side effects Market landscape for acne treatments1 ▪ BTX 1503 has multiple mechanisms of action that directly treat the key pathogenic factors causing
Slide 16: BTX 1503 key advantages
+BTX 1503 key advantages For personal use only Synthetic cannabidiol and a proprietary skin delivery system provides significant competitive advantages compared to other products in development Challenge 1 Challenge 2 Significant commercial and regulatory hurdles in extracting sufficient Medicinal c
Slide 17: BTX 1503 accelerated clinical development
+BTX 1503 accelerated clinical development For personal use only Botanix is pursuing a rapid clinical development strategy in order to minimise the time until product commercialisation and first revenues ▪ In December 2016, Botanix completed its first human study of the PermetrexTM delivery technolo
Slide 18: Accelerated development timeline
+Accelerated development timeline For personal use only Botanix is executing on an efficient, more economical and less risky clinical development strategy compared to traditional pharmaceutical development pathways Botanix’s accelerated indicative clinical timeline Proven ability to execute: Achieve
Slide 19: Commercialisation strategy
+Commercialisation strategy For personal use only Botanix’s focused and accelerated timeline to product commercialisation results in significant potential value uplift Efficient commercialisation path with multiple options Value uplift Significant value uplift potential at the ▪ Continued clinical d
Slide 20: Recent dermatology transactions
+Recent dermatology transactions For personal use only Licensing and partnering transactions are potential monetisation options Dermatology transactions US$5,200m Licensing deals US$790m Total upfront and US$770m milestone payments US$639m could exceed these US$445m figures in aggregate US$150m US$9
Slide 21: Clinical development pipeline
+Clinical development pipeline For personal use only Development pipeline also includes other synthetic cannabidiol clinical products targeting key dermatology markets These products will leverage both the BTX 1503 synthetic cannabidiol clinical program as well as the PermetrexTM delivery system BTX
Slide 22: OTC development pipeline
+OTC development pipeline For personal use only Development pipeline includes “over the counter” products with near term potential, that can be developed and marketed without FDA approval Top 10 facial cleaners based on sales Change in Unit sales Change in BTX 1701: cleanser/wash Sales (US$m) sales
Slide 23: Valuable intellectual property portfolio
+Valuable intellectual property portfolio For personal use only Botanix has protected its suit of development products through various patent applications across key global markets Expanded patent applications for BTX 1503 and other PermetrexTM ▪ Botanix currently has 12 patent applications enabled
Slide 24: Botanix vs. ASX-listed medical cannabis companies
+Botanix vs. ASX-listed medical cannabis companies For personal use only Botanix is the most compelling early stage cannabis related opportunity on the ASX Botanix’s competitive advantages: ▪ Synthetic cannabidiol formulation - probability and speed of FDA approval ▪ Unmet clinical need - No FDA a
Slide 25: ASX market landscape
+ASX market landscape For personal use only An accelerated clinical development timeline and near term catalysts should support a sustained re-rating in market valuation Botanix vs. early stage ASX-listed pharmaceutical and biotechnology companies Botanix’s clinical development pathway is de-risked
Slide 26: International landscape
+International landscape For personal use only Botanix represents a significant value accretive opportunity when compared to key global peers with positive Phase I and Phase II data Market capitalisation of key international peers1 Zynerba share price performance (US$) 24 US$1,383m Announced positiv
Slide 27: Key catalysts
+Key catalysts For personal use only Significant operational milestones expected over the next 9 months, as Botanix launches first human studies and accelerates corporate development 2Q CY2017 3Q/4Q CY2017 ▪ Study commencement of BTX 1503 Phase Ia ▪ Commencement (and completion) of BTX safety study
Slide 28: Appendix
For personal use only + Appendix Board of Directors, corporate history, commercialisation strategy, clinical development, and clinical team
Slide 29: Botanix Board of Directors
+Botanix Board of Directors For personal use only Highly credentialed Board of Directors with a proven record of building and leading successful pharmaceuticals businesses Graham Griffiths Matthew Callahan Dr Bill Bosch Rob Towner Chairman Executive Director Executive Director Director Appointed Jul
Slide 30: Botanix executive management
+Botanix executive management For personal use only Highly credentialed clinical development team with extensive expertise in leading novel products through clinical and regulatory development Dr Mark Davis Dr Michael Thurn Dr Gene Cooper VP Clinical and Regulatory Chief Operating Officer Consultant
Slide 31: Disclaimer
+Disclaimer For personal use only This presentation prepared by Botanix Pharmaceuticals Limited ("Company") does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction,
Slide 32: Disclaimer (cont.)
+Disclaimer (cont.) For personal use only Hong Kong WARNING: This document has not been, and will not be, registered as a prospectus under the Companies Ordinance (Cap. 32) of Hong Kong (the "Companies Ordinance"), nor has it been authorised by the Securities and Futures Commission in Hong Kong purs
Botanix Pharmaceuticals — Investor Presentation (April 2017) on 6ix